Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: a need for reappraisal of grading criteria R Madan, M Deebajah, S Alanee, NS Gupta, S Carskadon, N Palanisamy, ... Histopathology 74 (7), 1081-1087, 2019 | 25 | 2019 |
Systematic biopsy does not contribute to disease upgrading in patients undergoing targeted biopsy for PI-RADS 5 lesions identified on magnetic resonance imaging in the course … A Arabi, M Deebajah, G Yaguchi, M Pantelic, S Williamson, N Gupta, ... Urology 134, 168-172, 2019 | 17 | 2019 |
Barriers to obtaining prostate multi‐parametric magnetic resonance imaging in African‐American men on active surveillance for prostate cancer EL Walton, M Deebajah, J Keeley, S Fakhouri, G Yaguchi, M Pantelic, ... Cancer Medicine 8 (8), 3659-3665, 2019 | 17 | 2019 |
Endocrine, sexual function, and infertility side effects of immune checkpoint inhibitor therapy for genitourinary cancers A Sood, D Cole, F Abdollah, B Eilender, Z Roumayah, M Deebajah, ... Current urology reports 19, 1-9, 2018 | 16 | 2018 |
Phase I trial of intravesical Bacillus Calmette–Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after … S Alanee, S Sana, A El-Zawahry, J Peabody, T Pearce, N Adams, ... World journal of urology 39 (10), 3807-3813, 2021 | 14 | 2021 |
Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer ML Jamil, M Deebajah, A Sood, K Robinson, K Rao, S Sana, S Alanee BMJ open 9 (7), e028287, 2019 | 9 | 2019 |
Effect of lesion location on prostate cancer detection rate with magnetic resonance imaging targeted biopsy in African Americans E Walton, G Yaguchi, J Keeley, M Deebajah, M Menon, J Peabody, ... The Journal of urology 201 (3), 503-509, 2019 | 9 | 2019 |
MP43-09 PHASE I TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUéRIN COMBINED WITH INTRAVENOUS PEMBROLIZUMAB IN HIGH GRADE NONMUSCLE INVASIVE BLADDER CANCER. S Alanee*, A El-Zawahry, kevin McVary, M Deebajah, S Sana, ... The Journal of Urology 201 (Supplement 4), e620-e621, 2019 | 7 | 2019 |
A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate M Deebajah, J Keeley, H Park, M Pantelic, N Gupta, SR Williamson, ... Urologic Oncology: Seminars and Original Investigations 37 (8), 531. e1-531. e5, 2019 | 6 | 2019 |
Machine learning-based prediction of upgrading on magnetic resonance imaging targeted biopsy in patients eligible for active surveillance B ElKarami, M Deebajah, S Polk, J Peabody, B Shahrrava, M Menon, ... Urologic Oncology: Seminars and Original Investigations 40 (5), 191. e15-191 …, 2022 | 4 | 2022 |
Abstract CT047: Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous Pembrolizumab in high grade nonmuscle invasive bladder cancer S Alanee, AE Zawahry, S Sana, K McVary, K Robinson, KA Rao Cancer Research 79 (13_Supplement), CT047-CT047, 2019 | 4 | 2019 |
Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system … S Alanee, M Deebajah, A Dabaja, J Peabody, M Menon International urology and nephrology 54 (4), 799-803, 2022 | 3 | 2022 |
Post prostatectomy pathologic findings of patients with clinically significant prostate cancer and no significant PI-RADS lesions on preoperative magnetic resonance imaging S Alanee, M Deebajah, K Taneja, D Cole, M Pantelic, J Peabody, ... Urology 146, 183-188, 2020 | 3 | 2020 |
The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active … G Yaguchi, HJ Tang, M Deebajah, J Keeley, M Pantelic, S Williamson, ... Urologic Oncology: Seminars and Original Investigations 38 (6), 599. e9-599. e13, 2020 | 3 | 2020 |
Using adaptive genetic algorithms combined with high sensitivity single cell-based technology to detect bladder cancer in urine and provide a potential noninvasive marker for … S Alanee, M Deebajah, PI Chen, R Mora, J Guevara, B Francisco, ... Urologic Oncology: Seminars and Original Investigations 38 (3), 77. e9-77. e15, 2020 | 3 | 2020 |
Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for … ML Jamil, M Deebajah, A Sood, S Alanee BMJ open 9 (12), e027066, 2019 | 3 | 2019 |
Prostate volume measured by magnetic resonance imaging is not a predictor of lower urinary tract symptoms M Deebajah, M Bazzi, E Walton, M Pantelic, H Park, A Dabaja, S Alanee Journal of family medicine and primary care 8 (4), 1370-1373, 2019 | 3 | 2019 |
GATA3 Is a Useful Immunohistochemical Marker to Differentiate Variants of Renal Tubular Lesions from Different Segments of Renal Tubules M Deebajah, Z Qu, P Zhang | 2 | 2021 |
Prognostic significance of histomorphologic features of lymph node metastases in prostate cancer patients treated with radical prostatectomy: A single center study M Alhamar, A Jabbar, M Deebajah, M Diaz, S Alanee, O Hassan, ... Urologic Oncology: Seminars and Original Investigations 39 (12), 829. e1-829. e8, 2021 | 1 | 2021 |
MP15-11 a prospective study to examine the association of the urinary and fecal microbiome with prostate cancer and benign prostatic hyperplasia using 16srna analysis S Alanee, A El-Zawahry, M Karr, M Deebajah, A Dabaja, D Dynda, ... The Journal of Urology 199 (4S), e193-e193, 2018 | 1 | 2018 |